| Current Price | $28.75 | Mkt Cap | $1.0B |
|---|---|---|---|
| Open | $28.50 | P/E Ratio | 0.00 |
| Prev. Close | $28.75 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $27.87 - $29.11 | Volume | 522,892 |
| 52-Wk Range | $17.43 - $47.61 | Avg. Daily Vol. | 179,076 |
| Current Price | $28.75 | Mkt Cap | $1.0B |
|---|---|---|---|
| Open | $28.50 | P/E Ratio | 0.00 |
| Prev. Close | $28.75 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $27.87 - $29.11 | Volume | 522,892 |
| 52-Wk Range | $17.43 - $47.61 | Avg. Daily Vol. | 179,076 |
The best Bull and Bear pitches based on recency and number of recommendations.
Read the most recent pitches from players about ITOS.
Recs
BamaFool72
(< 20)
Submitted: 2/9/2021 12:21:08 PM :
Start Price:
$40.12
NASDAQ:ITOS Score:
-41.10
I also love the prospects for this company.
Recs
CMFMLove
(77.83)
Submitted: 2/9/2021 10:22:12 AM :
Start Price:
$39.80
NASDAQ:ITOS Score:
-40.63
Iteos Therapeutics, Inc is a small cap company focused on the development of biopharmaceuticals products and services. Iteos presently has two clinical-stage product candidates, Inupadenant (EOS-850) and EOS-448. Inupadenant targets the ATP adenosine pathway, while EOS-448 targets TIGIT (T cell immunoreceptor with immunoglobulin and ITIM domains). Anti-TIGIT is the next wave in oncology treatments and Iteos is one of the leaders. I think it will pay off big.
Find the members with the highest scoring picks in ITOS.
cruisin25 (61.54) Score: +5.55
The Score Leader is the player with the highest score across all their picks in ITOS.
|
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
|---|---|---|---|---|---|---|---|---|---|---|
| cruisin25 | 61.54 | 6/16/2021 |
|
3M | $26.36 | +9.73% | +4.19% | +5.55 | 0 Comment | |
| CMFMLove | 77.83 | 2/9/2021 |
|
5Y | $39.80 | -27.34% | +13.29% | -40.63 | 1 Comment | |
| BamaFool72 | < 20 | 2/9/2021 |
|
5Y | $40.12 | -27.92% | +13.19% | -41.10 | 1 Comment |
See what the Wall Street professionals think, according to their public statements and filings.
